Gilead Sciences is a biopharmaceutical company that focuses on the research, development, and commercialization of innovative therapeutics to address significant unmet medical needs, particularly in the fields of antiviral therapies, oncology, and inflammation. The company is well-known for its advancements in treatments for diseases such as HIV, hepatitis C, and influenza, while also expanding its portfolio to include oncology products and therapies for other serious conditions. Gilead is committed to improving patient outcomes through its cutting-edge science and collaborative efforts, working to develop medicines that have both transformative efficacy and address critical health challenges on a global scale.
Goldman Sachs analyst Salveen Richter highlights potential benefits for biopharma from 340B reforms, while Medicaid cuts could pose risks for companies with significant drug exposure.
Galapagos NV plans to split into two entities by mid-2025, focusing on oncology cell therapy and innovative medicines, with €2.45 billion allocated to SpinCo's pipeline.
JP Morgan highlights 2025 growth prospects for biopharma, animal health, and specialty pharma stocks. Key picks include Eli Lilly, Zoetis, and Bristol-Myers Squibb.
(BPT) - The summer spike in COVID-19 infections, triggered in part by a rise in new variants of the virus, was an unpleasant reminder that COVID-19 is here to stay. As we brace for an anticipated larger wave of COVID-19 cases during the fall and winter respiratory season, healthcare professionals want to remind the public that the virus does not affect everyone equally; some people, because of their age or overall health, may be at greater risk for severe illness.1,2
ICER's 2023 report highlights five drugs with unsupported price increases, leading to $815 million in excess costs for U.S. payers. Discover key findings and trends.
Gilead's once-yearly injectable lenacapavir shows promising results in HIV prevention, with a 96% reduction in infections and plans for regulatory filings by 2027.
